These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32042344)

  • 1. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.
    Papageorgis P; Polydorou C; Mpekris F; Voutouri C; Agathokleous E; Kapnissi-Christodoulou CP; Stylianopoulos T
    Sci Rep; 2017 Apr; 7():46140. PubMed ID: 28393881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
    Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
    J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
    Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
    Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.
    Mpekris F; Panagi M; Voutouri C; Martin JD; Samuel R; Takahashi S; Gotohda N; Suzuki T; Papageorgis P; Demetriou P; Pierides C; Koumas L; Costeas P; Kojima M; Ishii G; Constantinidou A; Kataoka K; Cabral H; Stylianopoulos T
    Adv Sci (Weinh); 2021 Feb; 8(3):2001917. PubMed ID: 33552852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.
    Panagi M; Mpekris F; Chen P; Voutouri C; Nakagawa Y; Martin JD; Hiroi T; Hashimoto H; Demetriou P; Pierides C; Samuel R; Stylianou A; Michael C; Fukushima S; Georgiou P; Papageorgis P; Papaphilippou PC; Koumas L; Costeas P; Ishii G; Kojima M; Kataoka K; Cabral H; Stylianopoulos T
    Nat Commun; 2022 Nov; 13(1):7165. PubMed ID: 36418896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
    Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
    Front Immunol; 2022; 13():938439. PubMed ID: 35812418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment.
    Jia N; Wang Q; Li W; Chen D; Hu H
    Adv Healthc Mater; 2024 Aug; 13(20):e2400219. PubMed ID: 38657266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.